).
Neurofibromatosis type 1 (NF1) is one of the most common genetic etiologies for pediatric brain tumors. 1, 2 As such, 15% -20% of children with NF1 develop low-grade glial neoplasms (pilocytic astrocytomas [PAs] ) arising along the optic pathway (optic nerve, chiasm, and postchiasmal tracts; optic pathway glioma [OPG] ). 3, 4 In some children with these NF1-OPGs, there may also be associated visual impairment 5, 6 or hypothalamic dysfunction. 7 Since surgery and radiation therapy are not used due to the risk of permanent nerve damage and secondary malignancy, 8 respectively, the treatment of NF1-OPG has largely employed agents (vincristine and carboplatin) in routine use for sporadic low-grade glioma. 9, 10 Because NF1-OPGs are rarely biopsied for pathological diagnosis, there have been few analyses of the molecular changes that drive tumorigenesis in this condition. Immunohistochemical and whole genome (NexGen) sequencing studies have demonstrated biallelic inactivation of both NF1 genes, 11 resulting in loss of NF1 protein (neurofibromin) expression in these NF1-associated brain tumors. 12, 13 To model the human condition in which children with NF1 are born with one functional and one nonfunctional (germline NF1 gene mutation) copy of the NF1 gene, Nf1+/2 mice with biallelic astroglial progenitor Nf1 gene loss were generated. 14, 15 These mice develop low-grade gliomas of the prechiasmatic optic nerves and chiasm with many similarities to their human counterparts. 14, 16, 17 As observed in human NF1-OPGs, these murine optic gliomas have low proliferative indices, increased microglia infiltration, and bipolar neoplastic glial cells with nuclear pleiomorphism and cellular atypia. 14, 16, 17 While complete NF1 gene inactivation is the rule for NF1-PA tumors, recent studies have revealed the presence of additional molecular changes in NF1-OPGs. 18, 19 In some of these NF1-OPGs, heterozygous PTEN deletion (1/4 tumors) and KIAA1549:BRAF duplication (1/4 tumors) were detected, raising the intriguing possibility that genetic cooperativity between these molecular alterations and neurofibromin loss might lead to more biologically aggressive tumors. To address this clinically relevant issue, we generated Nf1 genetically engineered mouse (GEM) strains that harbor Pten reduction or KIAA1549:BRAF expression in addition to Nf1 gene loss in neuroglial progenitors in vivo. Using these novel strains, we demonstrated that heterozygous Pten loss, but not KIAA1549:BRAF expression, cooperates with Nf1 gene inactivation to increase murine optic glioma growth and retinal nerve defects.
Materials and Methods

Mice
Nf1
flox/mut ; GFAP-Cre (FMC) mice (Nf1+/2 mice with Nf1 gene inactivation in neuroglial progenitors) were generated as previously described.
14 Nf1 flox/mut mice were intercrossed with Lox-Stop-Lox (LSL)-KIAA1549:BRAF (LSL-f-BRAF) mice, 20 and the resulting progeny were mated with Nf1 . 20 All mice were maintained on a C57Bl/6 background and used in accordance with approved animal studies protocols at the Washington University School of Medicine.
Primary Astrocyte Cultures
Primary astrocyte cultures were established from the brainstems of postnatal day1 -2 Nf1 flox/flox , Pten flox/wt or Nf1 flox/flox ; Pten flox/wt mouse pups, as described previously. 23 Wild-type (WT) cultures were generated following infection with adenovirus type 5 containing b-galactosidase (Ad5-LacZ; University of Iowa Gene Transfer Vector Core), while Nf12/2, Pten+/2, and Nf12/2; Pten+/2 cultures were generated following infection of Nf1 flox/flox , Pten flox/wt , or Nf1 flox/flox ; Pten flox/wt cultures, respectively, with adenovirus type 5 containing Cre recombinase (Ad5-Cre). Astrocyte proliferation was assessed using the BrdU Cell Proliferation ELISA kit (Roche) according to the manufacturer's instructions. 20 
Western Blotting
Cells were lysed in buffer containing 1% NP-40, supplemented with protease and phosphatase inhibitors. Western blotting was performed as described previously 24 using the following antibodies: PTEN, AKT, pAKT T308 (Cell Signaling Technology), and a-tubulin (Sigma). Chemiluminescence signal was detected using the ChemiDoc-It Imaging System (UVP) and quantified using Visionworks software (UVP). Immunoblot signals from phosphorylated AKT (pAKT T308 ) were normalized to total AKT to calculate relative AKT activation.
RNA Extraction and Real-time PCR
RNA was isolated from mouse optic nerves using Trizol reagent (Life Technologies) following the manufacturer's protocol. Total RNA was employed for cDNA synthesis using the SuperScript III first-strand synthesis system (Life Technologies).
The following primers were used for real-time (RT-PCR):
25,26
Optic Nerve Measurements
Optic nerves with an intact chiasm were microdissected and photographed, and the optic nerve diameters were measured at the chiasm ( 150, 300, and 450 microns anterior to the chiasm) to generate optic nerve volumes, as previously reported.
27
Immunohistochemistry Murine eyes and optic nerves were prepared for sectioning and immunostaining as previously described. 28 The following primary antibodies were used for immunostaining: Brn3a (Santa Cruz), SMI-32 (Covance), GFP (Abcam), Pten (Cell Signaling), GFAP (Millipore), Ki67 (Abcam), and Iba1 (Wako). For immunohistochemistry on paraffin sections, biotinylated secondary antibodies (Vector Laboratories) were used in combination with Vectastain Elite ABC kit and developed with 3,3
′ -diaminobenzidine peroxidase substrate kit and hematoxylin counterstaining. For fluorescencebased detection, species-appropriate Alexa-Fluor-conjugated (Invitrogen) secondary antibodies were used, followed by DAPI counterstaining. Amplification of the Brn3a antibody signal was performed using a biotinylated secondary antibody, followed by HRP conjugation using Vectastain Elite ABC kit, and the fluorescent signal was amplified with Tyramide Signal Amplification Plus Cyanine 3 system (Perkin-Elmer) according to the manufacturer's instructions. Terminal deoxynucleotide transferase-mediated dUTP nick-end labeling (TUNEL) staining was performed using the ApopTag Plus in situ apoptosis fluorescein detection kit (Millipore) according to the manufacturer's recommendations.
Manganese-enhanced MRI
MRI imaging to visualize the optic nerves in mice was performed as described previously. 27 
Retinal Analyses
Quantitation of TUNEL + cells was performed by counting the number of cells positive for TUNEL staining as a percentage of the total number of DAPI + cells in the retinal ganglion cell layer. The total number of Brn3a + cells was counted per section and normalized to control mice (set at 100%). Measurements of the retinal nerve fiber layer (RNFL) were performed following SMI-32 immunohistochemical staining using Image J software. Briefly, overlapping high-power images were taken at incremental distances from the optic nerve (21,1: 0 -250 mm; 22, 2: 250 -500 mm; 23, 3: 500 -750 mm; 24, 4: 750 -1000 mm; and 25, 5: ,1000 mm). Repeated measurements of the width of the stained axons (SMI-32 + staining) were recorded and averaged for each area. All quantitation was performed on sections through the optic nerve for a cohort of mice (n ¼ 3) corresponding to each genotype.
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Statistical Analysis
Data were analyzed using GraphPad Prizm 5.0 software using 2-way ANOVA for RNFL measurement data and Student t test for all other data comparisons with statistical significance set at P , .05. Scatter plot analysis examining the correlation between RNFL thickness and retinal ganglion cell (RGC) apoptosis was constructed using linear regression methods to generate the R 2 value in GraphPad Prizm 5.0 software.
Results and Discussion
The KIAA1549:BRAF rearrangement represents the signature genetic alteration observed in 50% -75% of sporadic PAs, in which the kinase domain of the BRAF gene is fused to the amino terminal exons of the KIAA1549 gene. 29, 30 The novel fusion protein generated by this molecular event (fusion-BRAF; f-BRAF) is hypothesized to create a molecule with constitutive BRAF kinase 29, 31 To determine the contribution of KIAA1549:BRAF (f-BRAF) to Nf1 murine optic glioma pathogenesis, Nf1+/2 mice were generated that conditionally express f-BRAF and lack Nf1 expression in neuroglial cells (Nf1 flox/mut ; f-BRAF; GFAP-Cre mice, FMBC mice) using the human GFAP-Cre transgenic mouse line. 25 Since antibody reagents do not exist to detect the KIAA1549:BRAF protein, we verified KIAA1549:BRAF transgene expression in the optic nerves by 2 different methods. First, we leveraged the green fluorescent protein (GFP) gene engineered into the KIAA1549:BRAF Rosa26 locus targeting vector as a surrogate marker of KIAA1549:BRAF transgene expression. GFP + cells were detected in the optic nerves of 1-month-old f-BRAF; GFAP-Cre (f-BRAF GFAP ) mice (Fig. 1A) . Second, the presence of the f-BRAF transcript was demonstrated in the optic nerves of f-BRAF GFAP mice by RNA RT-PCR using previously published primers. 25, 26 ( Fig. 1B) .
Despite robust KIAA1549:BRAF transgene expression, the optic nerves of FMBC mice (n ¼ 9) were indistinguishable from their FMC counterparts (n ¼ 8) with respect to optic nerve volume, GFAP expression, or histopathological appearance (H&E staining; Fig. 1C ) at 3 months of age. Similarly, microglia numbers (%Iba1 + cells) and proliferative indices (%Ki67 + cells) were similar to those observed in FMC optic nerves (Fig. 1D) . These results indicate that KIAA1549:BRAF expression does not confer any additional biological properties on murine Nf1 glioma growth.
Next, we sought to determine whether heterozygous Pten gene loss could synergize with Nf1 loss. For these studies, we generated Nf1+/2 mice with both absent Nf1 gene expression and reduced Pten gene expression in neuroglial progenitors (Nf1 flox/mut ; Pten flox/wt ; GFAP-Cre mice, FMPC mice). As expected, Pten expression was reduced, but not absent, in the optic nerves of FMPC mice relative to FMC optic nerves as revealed by Fig. S1A ). Similar to their FMC counterparts, focal enlargements of the optic nerves and chiasm were observed in all FMPC mice by smallanimal MRI ( Fig. 2A ) at 3 months of age. However, the optic nerves of FMPC mice (n ¼ 9) were larger when compared with FMC mice. In FMPC mice, we observed a 12% increase in nerve optic nerve volumes relative to FMC mice. When considering only the volume contributed by the tumor (after subtracting the volume of the normal nerves in FF control mice), FMPC mice exhibited a 55% increase in tumor volume compared with FMC mice (Fig. 2A , volume above the dotted line in the bar graph). In addition, these FMPC optic gliomas contained striking hypercellularity, increased numbers of atypical cells (H&E staining), and higher GFAP immunoreactivity relative to FMC mice (Fig. 2B) . Furthermore, there was a 4.6-fold increase in the percent of proliferating (Ki67 + ) cells and a 2.6-fold increase in the percent of infiltrating Iba1 + microglia in FMPC mice compared with FMC mice (Fig. 2C ). These findings demonstrate that Pten reduction cooperates with neurofibromin loss to increase Nf1 murine optic glioma growth in vivo.
The observation that Pten haploinsufficiency can impact NF1-associated tumor biology is further supported by GEM studies demonstrating that reduced Pten gene expression accelerates benign neurofibroma formation and malignant progression 32, 33 as well as the development of high-grade astrocytomas resulting from combined Nf1 and p53 gene inactivation 34 in mice. This cooperative effect likely reflects the activation of a common downstream growth regulatory effector (AKT). As such, while reduced Pten expression or Nf1 loss in primary astrocytes resulted in 1.5-fold and 2-fold increases in AKT activation (T308 phosphorylation), respectively, combined Nf1 loss and Pten reduction led to a 3-fold increase in AKT phosphorylation (Fig. 3A) . Similarly, whereas Pten reduction alone had no effect on astrocyte proliferation, Nf1 loss resulted in a 1.7-fold increase in proliferation, and astrocytes with both Nf1 loss and Pten reduction exhibited a 3-fold increase in proliferation (Fig. 3B) .
To determine whether Pten reduction increases Nf1-deficient astrocyte proliferation and optic glioma growth in an mTORdependent manner, we performed a series of experiments. First, inhibition of AKT activity using the MK2206 compound (50nM) suppressed both Nf1-deficient and Nf12/2;Pten+/2 astrocyte proliferation in vitro (Fig. 3C and D) . This inhibition of Nf1-deficient astrocyte proliferation is consistent with previous reports from our laboratory demonstrating that mTOR hyperactivation following neurofibromin loss requires AKT activity. 35, 36 To determine whether this cooperativity reflects convergence on mTOR, we measured mTOR activation as assessed by ribosomal S6 phosphorylation. Interestingly, there were no further increases in S6 phosphorylation in Nf12/2;Pten+/2 astrocytes in vitro or FMPC optic gliomas in vivo compared with Nf1-deficient astrocytes or FMC tumors, respectively (Supplementary material, Fig. S1B and C) . Since ribosomal S6 represents only one of many mTOR effectors, we examined the activation (phosphorylation status) of both mTOR complex 1 (C1) and complex 2 (C2) molecules. As observed with S6, no further increases were observed in mTORC1 (4E-BP1, PRAS40) or mTORC2 (AKT S473 , PKCa) effector activation (Supplementary material, Fig. S1C ). Taken together, these observations indicated that Pten heterozygosity likely 
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Neuro-Oncologyfunctions in an mTOR-independent manner to synergize with neurofibromin loss in the pathogenesis of NF1-OPG. These findings suggest that combinatorial therapy targeting both PI3K and mTOR may be useful in a subset of NF1-associated optic gliomas, similar to high-grade gliomas. 37, 38 Current studies using a combination of approaches are in progress to identify potential effectors that operate downstream of PTEN/PI3-Kinase.
Children with NF1-OPG often come to medical attention because of reduced visual function. 5, 39 Since these tumors arise in young preverbal children, it is often challenging to accurately assess their visual acuity, especially when compounded with behavioral and attention deficits common in this patient population. 40 -42 To circumvent these problems, objective measures have been sought. One of the recently applied methods involves optical coherence tomography to measure retinal nerve fiber layer thickness in children with OPG. 43 -45 In these studies, reduced ganglion cell-inner plexiform layer (GCL-IPL) thickness (,5th percentile) has been demonstrated to be an accurate surrogate marker of vision loss in children with OPG. 43, 46 For this reason, we analyzed the retina in the 3 Nf1 murine optic glioma strains at 3 months of age. Relative to control (FF) mice, FMC, FMBC, and FMPC mice exhibited an average 6-fold (range, 5.6% -6.9%) increase in RGC death (apoptosis; %TUNEL + cells; Fig. 4A and B) and an average 36% (range, 31% -45%) reduction Fig. 4 . Increased retinal ganglion cell dysfunction accompanies optic glioma formation in Nf1 mutant mice. (A) TUNEL staining (top panels), immunohistochemistry using Brn3a (middle panels), and SMI-32 (lower panels) reveal increased apoptosis (TUNEL + cells; arrows), retinal ganglion cell loss (Brn3a + cells, arrows), and retinal nerve fiber layer thickness (RNFL; SMI-32) in FMC, FMBC, and FMPC mice relative to FF control mice. The insets illustrate individual TUNEL + (top panels) and Brn3a + (middle panels) cells, whereas the insets in the lower panels demonstrate the RNFL thickness (yellow brackets). The percent of TUNEL + and Brn3a + cells are quantified in panels B and C, respectively. (D) Quantitation of the RNFL thickness as a function of the distance from the optic nerve head is illustrated above and graphically represented below. Scale bars, 100 mm; *, P , .05; **P , .01 ***, P , .001; n.s., not significant. Kaul et al.: Genetic cooperativity in Nf1 optic glioma in RGC number (%Brn3a + cells; Fig. 4A and C) . Using SMI-32 immunostaining (Fig. 4A) , we next calculated the RNFL thickness as a function of the distance from the optic nerve head (Fig. 4D) . We found an inverse correlation (R 2 ¼ 0.803) between RGC death (TUNEL-positive cells) and RNFL thickness in all 3 mouse models, supporting that RNFL thinning results from loss of RGCs (Supplementary material, Fig. 2 ). While the 3 Nf1 optic glioma mouse strains exhibited reduced RFNL thickness at all regions of the retina, FMPC mice had 3-fold reduced RNFL thickness proximate to the optic nerve head relative to control (FF) mice, compared with 2-fold reductions observed in FMC and FMBC mice in the same region.
Prior studies have shown that optic nerve axonal swelling and visual electrophysiological delays (visual evoked responses) precede RGC death in FMC mice, 47 such that restoring the reduced cyclic AMP levels in Nf1+/2 neurons ameliorates the optic glioma-associated RGC apoptosis. 48 Based on these findings, we hypothesize that the larger, more proliferative FMPC optic gliomas result in greater retinal dysfunction that is initially more evident in the optic nerve head closer to the optic nerve axons. Since reduced visual acuity by virtual optokinetic system testing is not detected until 6 months of age in FMC mice, 49 future studies are in progress to compare the visual acuity deficits in these different Nf1 optic glioma strains at older ages as well as to identify neuroprotective strategies to attenuate vision loss.
Collectively, these results reported herein demonstrate that Pten gene dose reduction, but not KIAA1549:BRAF expression, cooperates with neurofibromin loss to increase Nf1 optic glioma growth and RGC dysfunction and further underscore the utility of GEM strains for defining the biological significance of genetic alterations discovered by advanced genomic analysis in human pathological specimens.
Supplementary Material
Supplementary material is available at Neuro-Oncology Journal online (http://neuro-oncology.oxfordjournals.org/). 
